2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Melanoma
3
Squamous Cell Carcinoma of Head and Neck
2
Sezary Syndrome
2
Sarcoma
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Leukemia
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroblastoma
1
Neoplasms
1
Myelodysplastic Syndromes
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma
1
Liver Neoplasms
1
Leukemia-Lymphoma, Adult T-Cell
1
Interventions
Carboplatin
12
Pemetrexed
8
pembrolizumab
4
Paclitaxel
4
Cisplatin
4
durvalumab
3
Radiosurgery
3
Gemcitabine
3
selpercatinib
2
pralsetinib
2
osimertinib
2
camrelizumab
2
atezolizumab
2
Docetaxel
2
taletrectinib
1
repotrectinib
1
motexafin gadolinium
1
exemestane
1
entinostat
1
ceralasertib
1
cemiplimab
1
belinostat
1
belagenpumatucel L
1
alectinib
1
Vinorelbine
1
Tyrosine Kinase Inhibitors
1
TNFSF10 protein, human
1
Radiotherapy
1
Platinum Compounds
1
Patient Reported Outcome Measures
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Bronchogenic
×
Interleukin-15
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled